While studies to test the safety and efficacy of new drugs are necessary, their success cannot be guaranteed. In fact, it’s likely that at least 80...
In this exclusive interview with BioPharma BoardRoom, Jessay Devassy, Manager, Bioprocess Applications at Ecolab Bioprocessing&...
U.S. Food and Drug Administration announced its intent to expand the use of unannounced inspections at foreign manufacturing facilities that produc...
Net sales increased organically by 2.5% to € 5.3 billion EBITDA pre up organically by 5.8% to € 1.5 billion All three b...
10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31...
Core Illumina revenue of $1.04 billion for Q1 2025, down 1% from Q1 2024 (flat on a constant currency basis) GAAP operating margin...
Total revenues remain strong at CHF 7.2 billion (CHF 7.3 billion in 2023) Record CHF 833 million raised by privately funded companies drives 22%...
Inventiva , a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic...
Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated resu...
Delivered total first quarter revenue of $707 million, an increase of 11% on a reported and core revenue basis, including Screening revenue of ...
Purchase price of $47 per share in cash represents an enterprise value of €3.0 billion ($3.4 billion), or an equity value of approximately $...
In this exclusive interview with BioPharma BoardRoom, Mike Kadan, PhD, MBA, Chief Operating Officer of Vector BioMed, shares how the company is reimagining...
CEO Paul Hudson: Confidence in Full-Year Outlook Paul Hudson, Chief Executive Officer: “We had a strong start in 2025 with sales growth of 9.7%, b...
- Recorded Q1’25 consolidated revenue of KRW 1.3 trillion - Recorded Q1’25 consolidated operating profit of KRW 486.7 billion - Company exp...
© 2025 Biopharma Boardroom. All Rights Reserved.
